We propose that targeting skeletal muscle PAK1 may be of therapeutic benefit for T2D and that PAK1 may regulate an important new connection between glucose tolerance and lipid storage, delivery and metabolism. The gene discussed is PAK1; the disease is type 2 diabetes mellitus.